Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aileron Therapeutics Successfully Completes First-Ever Stapled Peptide Clinical Trial

Published: Thursday, May 09, 2013
Last Updated: Thursday, May 09, 2013
Bookmark and Share
Safety and pharmacokinetics of ALRN-5281, a long-acting growth-hormone-releasing-hormone agonist, established in single-ascending dose study.

Aileron Therapeutics, Inc. announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.

“The successful translation of a Stapled Peptide drug into human subjects has long been our goal. It is an important milestone for Aileron, as well as for the rapidly emerging Stapled Peptide field as a whole,” said Joseph A. Yanchik, III, president, chief executive officer and co-founder of Aileron. “We are proud to pioneer the first clinical trial of Stapled Peptides, and we look forward to continuing our leadership in the development and eventual commercialization of this promising therapeutic class.”

The initial Phase 1 trial evaluated the safety and tolerability of single ascending doses of ALRN-5281 administered by subcutaneous injection in healthy adult subjects. Additional study objectives included the evaluation of pharmacokinetics (PK) and exploratory pharmacodynamic (PD) biomarkers of ALRN-5281. Thirty-two subjects completed the study. There were no serious adverse events, dose-limiting safety findings, or tolerability issues leading to withdrawal during the study.

“We now have clinical data showing that Aileron’s Stapled Peptides are capable of delivering a drug product profile previously believed to be out of reach with traditional peptide-based therapeutics, in particular PK attributes that support once-weekly dosing,” said Hubert C. Chen, M.D., vice president of clinical development at Aileron. “We are encouraged by the prospects of ALRN-5281 to demonstrate improved safety, efficacy, and convenience over currently available GH and GHRH injections. The results of this initial trial will guide us in optimizing dose selection and frequency for ALRN-5281 as a potential best-in-class therapy.”

Stapled Peptides are a new class of drugs with a unique set of properties that fully capitalize on 25 years of genetic research to attack drivers of complex diseases, including cancer, endocrine/metabolic disorders and inflammation. The Stapled Peptide platform locks peptides into their biologically active shape and imparts pharmaceutical stability within the body. Stapled Peptide drugs, such as ALRN-5281, are derived from natural peptides and are designed to remain in a safe and effective therapeutic range longer than traditional peptide hormones. This new class of drugs represents a fundamental scientific breakthrough as they offer the most advanced way to replicate normal human physiology to treat human disease.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Honey’s Potential to Save Lives
The healing powers of honey have been known for thousands of years.
Muscles on-a-Chip
This study may help explain why stem cell-based therapies have so far shown limited benefits for heart attack patients in clinical trials.
3-D Printed Lifelike Liver Tissue for Drug Screening
A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!